Newsletter | July 21, 2026
FEATURED EDITORIAL
Reassessing Nanoparticle Immunotoxicity: From Well-Established To Novel Approaches
By Marina A. Dobrovolskaia, Frederick National Laboratory for Cancer Research
This article highlights government-funded resources available to de-risk nanomedicines, reviews principles of immunotoxicity testing, and discusses emerging methodologies.
MOST POPULAR NEWS
•
LigoLab Partners With MarginLogic Health AI To Deliver AI-Powered OCR For Laboratories
Roche Introduces Cobas Hepatitis D Virus (HDV) Test
Zoetis Announces Agreement To Acquire VitalRADS, Accelerating Diagnostic Capabilities
Revna Biosciences Completes German Development Grant Programme
Renew Biotechnologies Unifies Wasatch BioLabs & Resonant Under One Brand
The Jackson Laboratory Selected For ARPA-H THRIVE Award
Anthem Establishes Coverage Of C2N Diagnostics' PrecivityAD2 Blood Test
Devyser Announced The Launch Of Next Gen Chimerism Analysis Solution
bioMérieux To Showcase Company's Latest In Diagnostic Innovations At ADLM 2026
Castle Biosciences Announces NY State Dept Of Health Approval Of Its AdvanceAD-Tx Test
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic For Prostate Cancer
